执业放射科医师对静脉碘对比剂给药前预用药使用情况的调查
2020年10月通过电子邮件向ACR执业放射科医师会员发放匿名调查,用两个临床情景询问对既往中度碘对比剂过敏反应患者的预用药管理。11%(724/6616)回复;住院常规场景72%用皮质类固醇预用药,急诊紧急场景67%用预用药;急诊快速静脉预用药使用率2020年60%高于2009年29%(P<.001)。
要点
- 住院常规增强CT场景中72%(518/724)选择皮质类固醇预用药,28%(200/724)改做平扫CT。
- 急诊紧急增强CT场景中67%(487/724)选择皮质类固醇预用药,30%(217/724)改做平扫CT。
- 急诊快速静脉预用药使用率2020年60%(433/724)高于2009年29%(20/69),P<.001。
核心结论
- 自2009年以来,急诊紧急场景中快速静脉预用药的使用增加,与ACR指南更新一致,但关于需要一剂还是两剂皮质类固醇存在分歧。
- 尽管多数医师报告高度依赖ACR指南,偏离指南的情况仍常见;总体而言,未遵循ACR指南时偏向规避风险的方向。
研究设计与样本
- 研究类型为匿名问卷调查,2020年10月通过电子邮件发放给ACR执业放射科医师会员,回复率11%(724/6616),并与2009年历史对照比较。
- 调查设置两个临床情景:需在24小时内完成的住院患者增强CT,以及需在6小时内完成的急诊增强CT;两场景中患者均既往对碘对比剂有中度过敏反应。
诊断标准与关键数值
- 住院情景中72%(518/724)使用皮质类固醇预用药后行增强CT,28%(200/724)行平扫CT;急诊情景中67%(487/724)使用预用药后行增强CT,30%(217/724)行平扫CT。
- 常规住院患者倾向口服预用药(85%,439/518),急诊紧急患者倾向快速静脉预用药(89%,433/487)。
- 急诊提供快速静脉给药数据的医师中,53%(216/410)使用两剂皮质类固醇,45%(185/410)使用一剂。
- 学术放射科医师比私人或混合执业放射科医师更可能给予两剂(74%[74/100]vs 48%[151/312],P<.001,OR 3.03,95%CI 1.84-5.00)。
- 快速静脉预用药2020年使用率60%(433/724)高于2009年29%(20/69),P<.001,OR 3.65,95%CI 2.12-6.26。
临床应用与阅片要点
- 住院和急诊场景中抗组胺药使用均常见:住院93%(480/518),急诊92%(447/487)。
- 仅32%(229/721)的放射科医师做法符合ACR指南关于既往对钆对比剂有严重过敏反应者行增强CT前无需常规预用药的建议;但93%(670/724)表示ACR对比剂手册是其执业的主要决定因素。
局限性
- 回复率为11%(724/6616)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether updated guidance by the ACR in 2017 advocating use of intravenous (IV) premedication in emergency department (ED) patients and inpatients with reported iodinated contrast allergy was associated with a change in clinical practice.
METHODS: An anonymous survey was distributed via e-mail in October 2020 to practicing radiologist members of the ACR interrogating use of corticosteroid premedication for two clinical vignettes: an indicated routine (perform within 24 hours) inpatient contrast-enhanced CT (CE-CT) and an indicated urgent (perform within 6 hours) ED CE-CT. In both scenarios, the patient had a prior moderate hypersensitivity reaction to iodinated contrast media. Clinical management was evaluated. Data were compared to historical controls from 2009.
RESULTS: The response rate was 11% (724 of 6,616). For the inpatient scenario, 72% (518 of 724) would use corticosteroid premedication with CE-CT, and 28% (200 of 724) would perform noncontrast CT. For the ED scenario, 67% (487 of 724) would use corticosteroid premedication with CE-CT, and 30% (217 of 724) would perform noncontrast CT. Oral premedication (85%, 439 of 518) was preferred for routine inpatients, and rapid IV premedication (89%, 433 of 487) was preferred for urgent ED patients. Of those who provided rapid IV dosing data in the ED, two doses of corticosteroids were used by 53% (216 of 410) and one dose was used by 45% (185 of 410), with academic radiologists more likely than private or hybrid practice radiologists to administer two doses (74% [74 of 100] versus 48% [151 of 312], P < .001, odds ratio, 3.03; 95% confidence interval, 1.84-5.00). Rapid IV premedication was more commonly used in 2020 than in 2009 (60% [433 of 724] versus 29% [20 of 69], P < .001, odds ratio, 3.65; 95% confidence interval, 2.12-6.26). Antihistamine use was common in both inpatient (93%, 480 of 518) and ED settings (92%, 447 of 487). Only 32% (229 of 721) of radiologists practiced in accordance with ACR guidelines, suggesting no need for routine premedication before CE-CT in patients with prior severe hypersensitivity reaction to gadolinium-based contrast media. Nonetheless, most (93%, 670 of 724) said the ACR Manual on Contrast Media was a major determinant of their practice.
CONCLUSIONS: Use of rapid IV premedication in urgent settings has increased since 2009, following updated ACR guidelines, but there is disagreement over whether one or two corticosteroid doses is required. Despite reported high reliance on ACR guidelines, deviations from those guidelines remain common. In general, when ACR guidelines were not followed, it was in a risk-averse direction.
引用
- Sodagari F, Davenport MS, Asch D, et al. A Survey of Practicing Radiologists on the Use of Premedication Before Intravenous Iodinated Contrast Medium Administration. J Am Coll Radiol. 2023. PMID: 37516161. doi:10.1016/j.jacr.2023.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。